<table border="0" cellpadding="4" id="id_9902f511-58b6-4550-9810-65eeb2e4253c" width="80%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 14. Mean<linkhtml href="#footnote-1">*</linkhtml> Pharmacokinetic Parameters in Healthy Volunteers and Adult Patients With Epilepsy</caption>
<col span="1" width="21.5%"></col>
<col span="1" width="16.4%"></col>
<col span="1" width="20.9%"></col>
<col span="1" width="18.7%"></col>
<col span="1" width="22.5%"></col>
<tbody>
<tr>
<td>Adult Study Population</td>
<td>Number of Subjects</td>
<td>T<sub>max</sub>  : Time of <br/>Maximum <br/>Plasma Concentration <br/>(hr)</td>
<td>t<sub>½</sub>  : Elimination <br/>Half-life <br/>(hr)</td>
<td>C1/F: <br/>Apparent Plasma <br/>Clearance <br/>(mL/min/kg)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Healthy volunteers taking no other medications:</content>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Single-dose Lamotrigine</td>
<td>179</td>
<td>2.2 <br/>(0.25-12.0)</td>
<td>32.8 <br/>(14.0-103.0)</td>
<td>0.44 <br/>(0.12-1.10)</td>
</tr>
<tr>
<td>Multiple-dose Lamotrigine</td>
<td>36</td>
<td>1.7 <br/>(0.5-4.0)</td>
<td>25.4 <br/>(11.6-61.6)</td>
<td>0.58 <br/>(0.24-1.15)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Healthy volunteers taking valproate:</content>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Single-dose Lamotrigine</td>
<td>6</td>
<td>1.8 <br/>(1.0-4.0)</td>
<td>48.3 <br/>(31.5-88.6)</td>
<td>0.30 <br/>(0.14-0.42)</td>
</tr>
<tr>
<td>Multiple-dose Lamotrigine</td>
<td>18</td>
<td>1.9 <br/>(0.5-3.5)</td>
<td>70.3 <br/>(41.9-113.5)</td>
<td>0.18 <br/>(0.12-0.33)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Patients with epilepsy taking valproate only:</content>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Single-dose Lamotrigine</td>
<td>4</td>
<td>4.8 <br/>(1.8-8.4)</td>
<td>58.8 <br/>(30.5-88.8)</td>
<td>0.28 <br/>(0.16-0.40)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone</content>
<linkhtml href="#footnote-2">†</linkhtml>
<content stylecode="bold"> plus valproate:</content>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Single-dose Lamotrigine</td>
<td>25</td>
<td>3.8 <br/>(1.0-10.0)</td>
<td>27.2 <br/>(11.2-51.6)</td>
<td>0.53 <br/>(0.27-1.04)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone<footnoteref idref="id-c9bce751-583c-4f72-8e8f-34eb1c188919"></footnoteref>   :</content>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Single-dose Lamotrigine</td>
<td>24</td>
<td>2.3 <br/>(0.5-5.0)</td>
<td>14.4 <br/>(6.4-30.4)</td>
<td>1.10 <br/>(0.51-2.22)</td>
</tr>
<tr>
<td>Multiple-dose Lamotrigine</td>
<td>17</td>
<td>2.0 <br/>(0.75-5.93)</td>
<td>12.6 <br/>(7.5-23.1)</td>
<td>1.21 <br/>(0.66-1.82)</td>
</tr>
<tr>
<td>
<br/>
</td>
</tr>
</tbody>
</table>